Trust Bio-sonics' Ultrasound Enhancing Agent has Completed the Enrollment of the First Patient in its Phase III Study
03/20/2025
Date: 2025/ 3/ 20 Thu., Media: Global Bio & Investment
News Link：
Trust Bio-sonics announced that its new drug, TBS-002 ultrasound enhancing agent, focused on the diagnoses of cardiovascular diseases, has successfully enrolled the first patient in its Phase III clinical trial. The trial is expected to be completed by 2026.
- Check the news link for full details -